Search results
Potential Precursor Lesion to Adrenal Tumors Identified
Medscape· 4 days agoCortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...
Research shows linked biological pathways driving skin inflammation
Medical Xpress· 6 days agoLed by researchers at NYU Langone Health, the new study found that the interleukin-17 (IL-17)...
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 6 days agoThe board will seek public comments, additional information and data over the next 60 days to...
Studies Show Linked Biological Pathways Driving Skin Inflammation
WFRV 5 Green Bay· 6 days agoA certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 6 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace via Yahoo Finance· 6 days agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Ultravate side effects: What they are and how to manage them
Healthline· 7 days agoUltravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to serious. Specifically ...
Palisade's ulcerative colitis drug prevents symptoms in mice, is nontoxic in dogs
FierceBiotech· 3 days agoTwice-daily doses of Palisade's oral prodrug PALI-2108 for eight days protected mouse models of...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? | The Motley...
The Motley Fool· 6 days agoWall Street is feeling pretty good about AbbVie's (ABBV -1.19%) performance in 2024 so far. Chen...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Motley Fool via Yahoo Finance· 6 days agoLuckily, sales of Rinvoq, an arthritis tablet, and Skyrizi, a psoriasis injection, offset the loss....